AssetMark Inc
ANIP icon

AssetMark Inc’s ANI Pharmaceuticals ANIP Stock Holding History

AssetMark Inc’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.24K Buy
17
+6
+55% +$462 ﹤0.01% 3186
2026
Q2 		$911 Hold
11
– – ﹤0.01% 3167
2026
Q1 		$846 Buy
+11
New +$859 ﹤0.01% 3071
2018
Q1 		– Sell
-12
Closed -$1K – 1427
2017
Q4 		$1K Buy
+12
New +$747 ﹤0.01% 1545

Other funds holding ANIP

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Penn Capital Management
Penn Capital Management Philadelphia, Pennsylvania $1.37B AUM 42.56% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Thompson Siegel & Walmsley
Thompson Siegel & Walmsley Richmond, Virginia $5.37B AUM 3.99% 1-Year Est. Return
Marathon Capital Management
Marathon Capital Management Hunt Valley, Maryland $488M AUM 28.5% 1-Year Est. Return
Bridge City Capital
Bridge City Capital Lake Oswego, Oregon $480M AUM 47.16% 1-Year Est. Return
SEB Asset Management
SEB Asset Management Stockholm $27B AUM
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

AssetMark Inc's ANIP Position: Q3 2026 in Review

AssetMark Inc increased its ANI Pharmaceuticals (ANIP) stake by 55% in Q3 2026, buying an estimated $462 and bringing the position to 17 shares worth $1.24K. The position accounts for ﹤0.01% of the portfolio, ranked #3186.

AssetMark Inc first reported a position in ANIP in Q4 2017 and has held it in 4 quarters since. 94 funds tracked by Wall St. Rank hold ANIP as of Q3 2026.

  • AssetMark Inc held 17 shares of ANI Pharmaceuticals worth $1.24K as of Q3 2026.
  • AssetMark Inc bought 6 ANI Pharmaceuticals shares in Q3 2026, an estimated $462.
  • ANI Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #3186 holding.
  • AssetMark Inc first reported a position in ANI Pharmaceuticals in Q4 2017 and has held it in 4 quarters since.
  • 94 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.